ProCE Banner Activity

A031501 AMBASSADOR: Phase III Trial of Pembrolizumab vs Observation as Adjuvant Therapy for High-Risk Muscle-Invasive Urothelial Carcinoma

Conference Coverage

In this analysis of the randomized phase III A031501 AMBASSADOR trial, adjuvant pembrolizumab therapy for high-risk muscle-invasive urothelial carcinoma improved disease-free survival compared with observation.

Released: February 02, 2024


Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from AstraZeneca, Exelixis, Inc., and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.


Exelixis, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC